Combining the drug ramucirumab with the chemotherapy drug gemcitabine is showing to be a successful second line treatment for pleural mesothelioma. Ramucirumab is a type of immunotherapy drug called a monoclonal antibody, which targets and restricts proteins that stimulate blood vessel growth in tumors. The Lancet Oncology published the results[…]
Full Archive
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
Primary Outcome Measures Major Pathologic (Disease) Response of Tumor to Nivolumab Combined with Ipilimumab Before Surgery [ Time Frame: 24 months ] The response of participant’s tumor to treatment with nivolumab and ipilimumab before surgery by analyzing tissue samples collected from participant during surgery for the presence of cancerous tumour cells. Major pathologic response[…]
Mesothelioma Patient Health Improves a Year After Surgery
It could take time for mesothelioma patients to have better lung function after pleural mesothelioma surgery since some patients have better lung function a year after surgery compared to the days and weeks after the operation. Researchers in Japan published their findings in Integrative Cancer Therapies. There were 24 male[…]
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Primary Outcome Measures Response rate [ Time Frame: Up to 4 years after study activation ] Will be compared between arms. Secondary Outcome Measures Major pathologic response rate [ Time Frame: Up to 3 years ] The proportion of patients with a pathologic response will be calculated and compared between arms and 95% confidence intervals reported. The chi-square[…]
Tremelimumab and Durvalumab are a Good Second Line Treatment for Mesothelioma
Two immunotherapy drugs, tremelimumab and durvalumab, are showing to be a successful second line treatment for pleural mesothelioma when combined. This could mean that more treatments will be approved for the treatment of mesothelioma. The results of this phase II clinical trial were published in the Lancet Respiratory Medicine from[…]
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso)
Primary Outcome Measures To evaluate the efficacy of atezolizumab in patients with MPM in terms of DFS [ Time Frame: 12 weeks ] DFS, defined as the time from initiation of study treatment to first recurrence of disease or death for any cause, whichever occurs first. Secondary Outcome Measures To evaluate the safety of[…]
HITHOC After Pleurectomy and Decortication Surgery Can Improve Survival
There are some good results coming from a German study looking at Pleurectomy and Decortication surgery (P/D) being combined with HITHOC. Pleurectomy surgery is surgery that removes mesothelioma tumors but leaves the lung intact while HITHOC is a method of adding heated chemotherapy to the pleural area, sparing the rest[…]
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma (BIMES)
Primary Outcome Measures To evaluate the efficacy of the treatment [ Time Frame: From the date of randomization to the date of last follow up, assessed up to 24 months ] To determine the efficacy of M7824 in terms of the Progression Free Survival (PFS) assessed by the investigator according to the modified Response[…]
Radiation Does Not Improve Survival in Pleural Mesothelioma Patients
A study at the Duke University Medical Center has found that radiation does not extend survival in pleural mesothelioma patients. A dual registry analysis was performed to determine the effectiveness of aggressive surgery and radiation. Adjuvant radiation is recommended as a treatment by many cancer centers including the U.S. National[…]
ONCOFID-P Was Given Orphan Drug Status to Treat Pleural Mesothelioma
Pleural mesothelioma could soon have a new approved treatment option. The Food and Drug Administration just granted orphan drug status to ONCOFID-P for the treatment of the cancer. It is currently being studied for invasive bladder cancer, but data from lab and mice models is showing it could be beneficial[…]